Regulators said they have told Mylan that it should be paying higher rebates on sales of EpiPens through Medicaid. » Read More
New rules would limit a person from using short-term health plans to no longer than three months.
The satirical show comes as Shkreli appears in court on criminal fraud charges, the New York Post says.
Sarepta Therapeutics said regulators have requested additional data from a study for its muscle-wasting treatment.
Shares of Alexion fell nearly 12 percent Monday after the pharmaceutical company said it missed its goal in a late-stage trial of the drug Solaris.
Enrollment on Obamacare exchanges has lagged original projections.
Valeant's CEO Joseph Papa says some of the firm's businesses are doing fine, but weak earnings and yet another downgrade sent the stock plunging.
Hillary Clinton faced flak after reportedly wearing an Armani jacket worth more than $12,000 during a speech about inequality.
Pharma bad boy Martin Shkreli unloaded as he left the federal courthouse in Brooklyn Monday.
The ex-Turing Pharmaceuticals CEO is charged with looting a pharma company he founded to pay off investors he was suspected of scamming.
Valeant Pharmaceuticals reported a lower-than-expected quarterly profit and cut its full-year earnings and revenue forecast.
As the world's largest cancer research conference gets underway, here's how to play the stocks.
Alzheimer's patients might be showing early warning signs that are missed by tests. Some researchers say they know one way to change that.
Spending on cancer medicines totaled $107 billion in 2015 and will exceed $150 billion by 2020, the IMS Institute for Healthcare Informatics says.
Insurance plans sold on Obamacare marketplaces were projected to see lower price hikes than plans sold outside.
Forbes reduced its estimate of the net worth of Elizabeth Holmes, the founder and CEO of Theranos, to zero from $4.5 billion last year.
Former Wells Fargo CEO Dick Kovacevich says Theranos is experiencing "normal things" common to start-ups.
Get the best of CNBC in your inbox